Go Pro

Rodman & Renshaw's Rating of Quantum Biopharma on 8/31/2026

On August 31, 2026, Rodman & Renshaw updated its outlook on Quantum Biopharma (CVE:QNT) with the action "Upgrade", setting a "Strong-Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Rodman & Renshaw

DateCompanyAction
9/28/2026
Agenus Inc. stock logo
AGEN
Agenus
Initiated Coverage
9/24/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Initiated Coverage
9/24/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Initiated Coverage
8/31/2026
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
Initiated Coverage
7/30/2026
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
Initiated Coverage
7/23/2026
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
Initiated Coverage
More Ratings From Rodman & Renshaw